120 related articles for article (PubMed ID: 7683229)
1. Is there a role for MACOP-B in the treatment of diffuse large cell lymphoma?
O'Reilly SE; Connors JM
Leuk Lymphoma; 1993; 10 Suppl():85-9. PubMed ID: 7683229
[TBL] [Abstract][Full Text] [Related]
2. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
Vitolo U; Bertini M; Brusamolino E; Cavallero GB; Comotti B; Gallo E; Ghio R; Levis A; Luxi G; Meneghini V
J Clin Oncol; 1992 Feb; 10(2):219-27. PubMed ID: 1370690
[TBL] [Abstract][Full Text] [Related]
3. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
4. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
5. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
6. MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Bartlett NL; Kwak LW; Horning SJ
Cancer; 1993 Jun; 71(12):4034-42. PubMed ID: 7685238
[TBL] [Abstract][Full Text] [Related]
7. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.
Hoskins PJ; Ng V; Spinelli JJ; Klimo P; Connors JM
J Clin Oncol; 1991 Feb; 9(2):220-6. PubMed ID: 1703227
[TBL] [Abstract][Full Text] [Related]
8. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
[TBL] [Abstract][Full Text] [Related]
9. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
10. Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse.
Hoskins PJ; Le N; Gascoyne RD; Klasa R; Shenkier T; O'Reilly S; Connors JM
Ann Oncol; 1997 Nov; 8(11):1125-32. PubMed ID: 9426332
[TBL] [Abstract][Full Text] [Related]
11. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
[TBL] [Abstract][Full Text] [Related]
13. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
Kwak LW; Wilson M; Weiss LM; Doggett R; Dorfman RF; Warnke RA; Horning SJ
J Clin Oncol; 1991 Aug; 9(8):1426-31. PubMed ID: 1712837
[TBL] [Abstract][Full Text] [Related]
14. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
Gemmati D; Ongaro A; Tognazzo S; Catozzi L; Federici F; Mauro E; Della Porta M; Campioni D; Bardi A; Gilli G; Pellati A; Caruso A; Scapoli GL; De Mattei M
Haematologica; 2007 Apr; 92(4):478-85. PubMed ID: 17488658
[TBL] [Abstract][Full Text] [Related]
15. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
16. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
[TBL] [Abstract][Full Text] [Related]
17. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B.
Bertini M; Orsucci L; Vitolo U; Levis A; Todeschini G; Meneghini V; Novero D; Tarella C; Gallo E; Luxi G
Ann Oncol; 1991; 2(10):733-7. PubMed ID: 1724908
[TBL] [Abstract][Full Text] [Related]
18. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
[TBL] [Abstract][Full Text] [Related]
19. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D
J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207
[TBL] [Abstract][Full Text] [Related]
20. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
Krieger G; Kreysing E; Kneba M
Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
